NCT02238483

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 213 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.

Conditions

• Chronic Obstructive Pulmonary Disease COPD

Interventions

Type	Name	Description
DRUG	AZD7624 1.0 mg	Inhaled AZD7624 solution, 11 mg/mL
DRUG	Placebo	Inhaled placebo solution

Timeline

• Start date: 2014-10-28
• Primary completion: 2016-04-04
• Completion: 2016-04-04
• First posted: 2014-09-12
• Last updated: 2018-05-24
• Results posted: 2018-04-18

Locations

41 sites across 6 countries: United States, Argentina, Chile, Netherlands, Peru, South Africa

Regulatory

• FDA-regulated drug study